missing translation for 'onlineSavingsMsg'
Learn More
Learn More
R&D Systems™ Recombinant Human ICOS Fc Chimera Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Marke: R&D Systems™ 169-CS-050
Additional Details : Gewicht : 0.00970kg
Beschreibung
Measured by its ability to inhibit human T cell proliferation induced by rhB7-H2/Fc Chimera in the presence of anti-CD3. Wang, S. et al. (2000) Blood 96:2808. The ED50 for this effect is 1-4 μg/mL in the presence of 3 μg/mL Recombinant Human B7-H2 Fc Chimera (Catalog # 165-B7 ) and at least 20 ng/mL of anti-CD3. Optimal dilutions should be determined by each laboratory for each application.Spezifikation
| Q9Y6W8 | |
| Lyophilized from a 0.2 μm filtered solution in PBS. | |
| M.W. (Observed): 50-60 kDa, reducing conditions; M.W. (theoretical): 40.3 kDa (monomer) | |
| 50 μg | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution. | |
| <0.10 EU / 1 μg of the protein by the LAL method. | |
| Unconjugated | |
| Reconstitute at 100 μg/mL in sterile PBS. | |
| ICOS |
| Bioactivity | |
| 29851 | |
| ICOS Fc Chimera | |
| Mouse myeloma cell line, NS0-derived human ICOS protein Human ICOS (Glu21-Phe141) (N-terminus) Accession # Q9Y6W8 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus) | |
| Disulfide-linked homodimer | |
| ICOS | |
| Recombinant | |
| >90%, by SDS-PAGE under reducing conditions and visualized by silver stain. |